Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ Cetuximab Chimeric Recombinant Rabbit Monoclonal Antibody (C225 (Cetuximab))
GREENER_CHOICE

Catalog No. PIMA547860
Change view
Click to view available options
Quantity:
200 μg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
PIMA547860 200 μg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. PIMA547860 Supplier Invitrogen™ Supplier No. MA547860
Add to Cart
Add to Cart

Rabbit Recombinant Monoclonal Antibody

Specificity: Recognises human EGFR.

Cetuximab (Erbitux) is a chimeric (mouse/human) monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer. Cetuximab, as an epidermal growth factor receptor (EGFR) inhibitor, binds to EGFR.
TRUSTED_SUSTAINABILITY

Specifications

Antigen Cetuximab Chimeric
Applications Flow Cytometry, Inhibition Assays
Classification Recombinant Monoclonal
Clone C225 (Cetuximab)
Concentration 1 mg/mL
Conjugate Unconjugated
Formulation PBS with 0.02% ProClin 300
Gene CD7
Gene Accession No. P09564
Gene Alias Erbitux; Fab C225; IMC-225
Host Species Rabbit
Immunogen human EGFR.
Purification Method Protein A
Quantity 200 μg
Regulatory Status RUO
Primary or Secondary Primary
Gene ID (Entrez) 924
Target Species Human
Content And Storage Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Product Type Antibody
Form Liquid
Isotype IgG κ
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.